Evidence map›Paper›PMID 32230902›Full record

ArticleVaccines2020

Recombinant Measles AIK-C Vaccine Strain Expressing Influenza HA Protein.

Takashi Ito, Takuji Kumagai, Yoshiaki Yamaji, Akihito Sawada, Tetsuo Nakayama

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Takashi ItoLaboratory of Viral Infection II, Kitasato Institute for Life Sciences, Tokyo 108-8641, Japan.
Takuji KumagaiKumagai Pediatric Clinic, Sapporo 004-0051, Japan.
Yoshiaki YamajiLaboratory of Viral Infection II, Kitasato Institute for Life Sciences, Tokyo 108-8641, Japan.
Akihito SawadaLaboratory of Viral Infection II, Kitasato Institute for Life Sciences, Tokyo 108-8641, Japan.
Tetsuo NakayamaLaboratory of Viral Infection II, Kitasato Institute for Life Sciences, Tokyo 108-8641, Japan.
Kitasato Institute Hospital · JPKasugai Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant measles AIK-C vaccine expressing the hemagglutinin (HA) protein of influenza A/Sapporo/107/2013(H1N1pdm) (MVAIK/PdmHA) was constructed. Measles particle agglutination (PA) and influenza hemagglutinin inhibition (HI) antibodies were induced in cotton rats immunized with MVAIK/PdmHA. Cotton rats immunized with two doses of the HA split vaccine were used as positive controls, and higher HI antibodies were detected 3 weeks after the first dose. Following the challenge of A/California/07/2009(H1N1pdm), higher viral loads (10

Indexed as

hemagglutininHI antibodiesinfluenza virusmeasles AIK-Crecombinant virus

Identifiers

PMID32230902
PMCPMC7349030
OpenAlexW3013396554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.